Journal article
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease
Abstract
Patients with chronic kidney disease (CKD) carry a high cardiovascular (CV) risk. Since whether this risk is reduced by aspirin is unclear, we examined if the effect of aspirin on cardiovascular outcomes varied by baseline kidney function in a primary cardiovascular disease prevention trial. The International Polycap Study-3 (TIPS-3) trial had randomized people without previous cardiovascular disease to aspirin (75 mg daily) or placebo. We now …
Authors
Mann JFE; Joseph P; Gao P; Pais P; Tyrwhitt J; Xavier D; Dans T; Jaramillo PL; Gamra H; Yusuf S
Journal
Kidney International, Vol. 103, No. 2, pp. 403–410
Publisher
Elsevier
Publication Date
2 2023
DOI
10.1016/j.kint.2022.09.023
ISSN
0085-2538